OAM
VYGR icon

Oxford Asset Management’s Voyager Therapeutics VYGR Stock Holding History

Oxford Asset Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,646
Closed -$60.4K – 724
2024
Q4 		$60.4K Buy
+10,646
New +$68.6K 0.03% 416
2019
Q4 		– Sell
-43,067
Closed -$741K – 2121
2019
Q3 		$741K Buy
43,067
+5,797
+16% +$122K 0.02% 1092
2019
Q2 		$1.01M Buy
37,270
+10,688
+40% +$245K 0.02% 967
2019
Q1 		$509K Sell
26,582
-40,083
-60% -$522K 0.01% 1209
2018
Q4 		$627K Buy
+66,665
New +$855K 0.02% 1093

Other funds holding VYGR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Oxford Asset Management's VYGR Position: Q1 2025 in Review

Oxford Asset Management sold out of Voyager Therapeutics (VYGR) in Q1 2025, closing a stake of 10,646 shares — an estimated $60.4K sold.

Oxford Asset Management first reported a position in VYGR in Q4 2018 and held it in 5 quarters. The position peaked at $1.01M in Q2 2019. 116 funds tracked by Wall St. Rank hold VYGR as of Q1 2025.

  • Oxford Asset Management reported no remaining Voyager Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Oxford Asset Management sold 10,646 Voyager Therapeutics shares in Q1 2025, an estimated $60.4K.
  • Oxford Asset Management first reported a position in Voyager Therapeutics in Q4 2018 and held it in 5 quarters.
  • Oxford Asset Management's Voyager Therapeutics position peaked at $1.01M in Q2 2019.
  • 116 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2025.

Based on Oxford Asset Management's 13F filing for Q1 2025, filed 15 May 2025.